Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Claritin ANDAs

This article was originally published in The Tan Sheet

Executive Summary

FDA has determined it may approve abbreviated new drug applications for Schering-Plough's Claritin Hives Relief Syrup (5 mg/5 mL loratadine) because the product "was not withdrawn from sale for reasons of safety or effectiveness," a notice in the Federal Register Feb. 2 states. Schering received approval for the product in November 2003 (1"The Tan Sheet" Nov. 24, 2003, p. 9). Although the firm sells a Hives Relief tablet, the syrup formulation was never marketed. The decision by the agency came in response to a February 2005 citizen petition submitted by Silarx Pharmaceuticals. The syrup will continue to be listed on the "Discontinued Product List" section of the Orange Book, FDA says...
Advertisement

Related Content

Claritin Hives Relief Approval Could Close Out Rx Product Line
Claritin Hives Relief Approval Could Close Out Rx Product Line

Topics

Advertisement
UsernamePublicRestriction

Register

PS099064

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel